根据Scorpius Holdings, Inc.最近向美国证券交易委员会提交的8-K文件，这家市值136万美元的制药公司已通过向一家机构投资者发行不可转换本票签订了一项重大确定性协议。 根据 InvestingPro 的数据，该公司的短期债务目前超过其流动资产，流动比率为0.62。该本票于周四发行，本金金额为60万美元，年利率为5.0%。

Scorpius Holdings, Inc., a pharmaceutical company with a market capitalization of $1.36 million, has entered into a material definitive agreement through the issuance of a non-convertible promissory ...

Scorpius (NYSE:SCPX) said it intends to offer to sell shares of its common stock to the public in an underwritten public offering.The company said it intends to use the net proceeds primarily for ...

Scorpius announced its collaboration with KaloCyte. Under this initial project, Scorpius will utilize its scientific and technical expertise to ...

Scorpius BioManufacturing officials announce that the original $650 million deal to build a vaccine and biologic medicine ...

Scorpius Holdings, Inc. DURHAM, N.C., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and ...

Scorpius Holdings, Inc. DURHAM, N.C., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and ...

Scorpius Holdings, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer.

Partnership highlights Scorpius’ expertise in supporting innovative therapeutic programsDURHAM, N.C., Jan. 22, 2025 (GLOBE ...

DURHAM, N.C., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (“CDMO”), ...